干扰素β-1B对多发性硬化症患者骨矿物质密度的影响。
The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients.
作者信息
Varoglu Asuman Orhan, Varoglu Erhan, Bayraktar Rezzan, Aygul Recep, Ulvi Hizir, Yildirim Kadir
机构信息
Departments of Neurology, Medical Faculty, Ataturk University, Erzurum, Turkey.
出版信息
J Back Musculoskelet Rehabil. 2010;23(1):25-9. doi: 10.3233/BMR-2010-0244.
OBJECTIVE
Osteoporosis is a secondary problem in multiple sclerosis (MS) patients. There have been only a few reports about the effect of interferon beta (IFNB) 1b on bone mineral density (BMD). We aimed to determine bone mass in patients using IFNB 1b.
METHODS
We enrolled 17 patients taking IFNB 1b (group I), 15 patients not taking IFNB (group II). We measured the BMD and T scores values and the patients were distinguished as normal, osteopenia and osteoporosis.
RESULTS
In the lumbar spine, there was no difference between groups I and II (p=0.3). In the left femur, no significant difference was detected between groups I and II (p=1). There was an inverse correlation between the BMD at the both regions and the Expanded Disability Status Scale score (r= -0.39, p=0.03; r=-0.52, p=0.002, respectively).
CONCLUSION
IFNB 1b may be used safely in MS patients, even in those undergoing pulse steroid therapies, because IFNB 1b has no effect on BMD.
目的
骨质疏松是多发性硬化症（MS）患者的一个继发性问题。关于β-干扰素（IFNB）1b对骨密度（BMD）影响的报道仅有几例。我们旨在确定使用IFNB 1b的患者的骨量。
方法
我们纳入了17名使用IFNB 1b的患者（I组），15名未使用IFNB的患者（II组）。我们测量了骨密度和T值，并将患者区分为正常、骨量减少和骨质疏松。
结果
在腰椎，I组和II组之间无差异（p = 0.3）。在左股骨，I组和II组之间未检测到显著差异（p = 1）。两个区域的骨密度与扩展残疾状态量表评分之间存在负相关（分别为r = -0.39，p = 0.03；r = -0.52，p = 0.002）。
结论
IFNB 1b对骨密度无影响，因此即使在接受脉冲类固醇治疗的MS患者中也可安全使用。
Zotero 插件